Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of PH94B Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder

NCT04754802 is registered in ClinicalTrials.gov with VistaGen Therapeutics, Inc. as lead sponsor.

NCT NCT04754802
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04754802 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of PH94B Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder
Lead sponsor
VistaGen Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 24, 2021
Completion date
June 22, 2022
Enrollment
224 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

social anxiety disorder